Recently added

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

Zatse, Christina; Garazi, Serna; Bernatowicz, Kinga; Amat Ferrer, Ramon; Prior, Olivia; Frigola Rissech, Joan; Ligero, Marta; Grussu, Francesco; Nuciforo, Paolo; Toledo, Rodrigo; ESCOBAR, MANUEL; GARRALDA, Elena; Perez-Lopez, Raquel; FELIP, ENRIQUETA (BMJ, 2025-01)

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

SORIA RIVAS, AINARA; Sanmamed, Miguel F.; MUÑOZ COUSELO, EVA; Sandhu, Shahneen; Long, Georgina; Spreafico, Anna (American Association for Cancer Research, 2025-02-24)

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer

Pathak, Neha; Oliveira, Mafalda (Annual Reviews, 2025)

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

IACOBONI, GLORIA; CABALLERO GONZÁLEZ, ANA CAROLINA; Delgado Serrano, Javier; BASTOS, MARIANA; Martínez-Cibrian, Nuria; Barba, Pere; Navarro Garces, Victor (Wiley, 2025-02-04)

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

Liposits, Gabor; taieb, julien; Fakih, Marwan; Prager, M.D., Gerald; Van Cutsem, Eric; Ciardiello, Fortunato; Tabernero, Josep (Frontiers Media, 2025-01-16)

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction ﻿

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma ﻿

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer ﻿

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study ﻿

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer ﻿

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer